Israel Active

Israel’s NeuroKaire (previously Genetika+ see ) has launched BrightKaire, the world’s first blood test to personalize depression treatment. It uses AI and stem cell tech to match patients with major depressive disorder (MDD) to effective medications. Approved in US and Israel.

Members and supporters of Hadassah, The Women’s Zionist Organization of America, pledged $23 million for Hadassah Medical Organization, its Jerusalem medical center, as well as programs in Israel and the US. It includes $5 million for a neurorehabilitation center and $3 million for IVF.

Scientists from Israel’s Weizmann Institute, and Anderson Cancer Center in Houston, have discovered the cause of cachexia – deadly weight loss responsible for roughly one-third of global cancer deaths. Targeted blockade of the right vagus nerve could prevent onset of cachexia.

Israel’s MediWound (see previously) has successfully completed a Phase III trial that shows its EscharEx topical, non-surgical treatment to wound bed preparation ensures a much quicker recovery for venous leg ulcers. Trials on diabetic foot ulcers are being planned.

Surgeons at Tel Aviv Sourasky (Ichilov) Medical Center performed Israel's first-ever minimally invasive brain surgery through the eye socket. Surgeons successfully removed a rare skull base tumor without the need to open the skull.

24 years ago, Prof Simcha Yagel delivered premature baby Ruhama, weighing just 495 grams, at Jerusalem’s Hadassah Mount Scopus Hospital. Ruhama has just returned to the same hospital – to give birth to her first child – a boy.  And Prof Yagel was present at that delivery too.

Israel’s OncoHost (see previously) has been selected as the Top Precision Oncology Solution for 2025 by Life Sciences Review. OncoHost’s PROphet® predicts how a specific immunotherapy treatment will perform on a cancer patient, from a single blood sample.

The US FDA has approved generic liraglutide injection from Israel’s Teva. It copies Novo Nordisk’s obesity drug Saxenda, which costs over $1,300 per month. Liraglutide mimics the body’s glucagon-like peptide-1 hormone, suppressing appetite and triggering insulin release for up to 24 hours.

Israel’s QuantHealth.ai (see previously) has successfully simulated 350+ clinical trials, with 90% predictive accuracy. Its 23 therapeutic areas, include oncology, immunology, cardio-metabolic diseases, and gastroenterology. It saved one top 10 customer $31.4 million.

Hebrew University of Jerusalem scientists have developed a technique that distinguishes the precise subgroup of a bacteria strain that is causing infection. It explains why antibiotics and vaccines sometimes fail. The discovery can lead to more precise treatments.